视网膜中央静脉阻塞的华氏巨球蛋白血症1例_Chinese Journal of Ocular Fundus Diseases

Authors：

李欢欢 ¹ , 王飞 ² , 高郁茹 ¹ , 晏丽 ¹ , 吕旭菁 ¹ ,  刘瑶 ¹

1. ;
2. ;

Corresponding author：

刘瑶, Email: Jiahl2000@163.com

Keywords：

视网膜中央静脉阻塞; 巨球蛋白血症; 多模式影像; 病例报告

DOI：

10.3760/cma.j.cn511434-20240708-00257

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

1.	Gertz MA. Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2023, 98(2): 348-358. DOI: 10.1002/ajh.26796.
2.	Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994[J]. Cancer, 1998, 82(6): 1078-1081. DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3.
3.	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. DOI: 10.1182/blood-2016-01-643569.
4.	Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome[J]. Blood, 2012, 119(10): 2205-2208. DOI: 10.1182/blood-2011-04-347690.
5.	Central Vein Occlusion Study Coordinating Center. Baseline and early natural history report. The Central Vein Occlusion Study[J]. Arch Ophthalmol, 1993, 111(8): 1087-1095. DOI: 10.1001/archopht.1993.01090080083022.
6.	中国抗癌协会血液肿瘤专业委员会中华医学会血液学分会中国华氏巨球蛋白血症工作组. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.Hematology Oncology Committee of China Anti- Cancer Association, Chinese Society of Hematology, Chinese Medical Association, Chinese Working Group of Walderström Macroglobulinemia. Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2022)[J]. Chin J Hematol, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.
7.	Pérez-Rueda A. Leukemic retinopathy secondary to hyperviscosity syndrome in acute lymphoblastic leukemia before and after treatment[J]. J Fr Ophtalmol, 2021, 44(3): 477-479. DOI: 10.1016/j.jfo.2020.04.039.
8.	Shrestha S, Poddar E, Bashyal B, et al. Bilateral central retinal vein occlusion as an initial presentation of Waldenstrom macroglobulinemia: a case report[J]. J Med Case Rep, 2023, 17(1): 59. DOI: 10.1186/s13256-023-03778-4.
9.	Hayreh SS, van Heuven WA, Hayreh MS. Experimental retinal vascular occlusion. I. pathogenesis of central retinal vein occlusion[J]. Arch Ophthalmol, 1978, 96(2): 311-323. DOI: 10.1001/archopht.1978.03910050179015.
10.	Schatz MJ, Wilkins CS, Otero-Marquez O, et al. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis[J/OL]. Case Rep Ophthalmol Med, 2021, 2021: 6816195[2021-12-15]. https://pubmed.ncbi.nlm.nih.gov/34956683/. DOI: 10.1155/2021/6816195.
11.	Baker PS, Garg SJ, Fineman MS, et al. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases[J]. Am J Ophthalmol, 2013, 155(3): 448-455. DOI: 10.1016/j.ajo.2012.09.018.
12.	Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies[J]. J Clin Oncol, 2020, 38(11): 1198-1208. DOI: 10.1200/JCO.19.02314.
13.	Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenström macroglobulinemia[J]. J Clin Oncol, 2018, 36(27): 2755-2761. DOI: 10.1200/JCO.2018.78.6426.
14.	Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase[J]. J Med Chem, 2019, 62(17): 7923-7940. DOI: 10.1021/acs.jmedchem.9b00687.
15.	Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study[J]. Blood, 2020, 136(18): 2038-2050. DOI: 10.1182/blood.2020006844.
16.	Kumar SK, Callander NS, Adekola K, et al. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology[J/OL]. J Natl Compr Canc Netw, 2024, 22(1D): e240001[2024-01-01]. https://pubmed.ncbi.nlm.nih.gov/38244272/. DOI: 10.6004/jnccn.2024.0001.
17.	Plante MM, Kimbrough EO, Agarwal AK, et al. Hyperviscosity syndrome induced bilateral visual and auditory impairment in therapy resistant Waldenström macroglobulinemia with MYD88 and CXCR4 mutations[J]. J Blood Med, 2023, 14: 639-648. DOI: 10.2147/JBM.S424072.
18.	Chanana B, Gupta N, Azad RV. Case report: bilateral simultaneous central retinal vein occlusion in Waldenström's macroglobulinemia[J]. Optometry, 2009, 80(7): 350-353. DOI: 10.1016/j.optm.2008.12.007.
19.	Thomas EL, Olk RJ, Markman M, et al. Irreversible visual loss in Waldenström's macroglobulinaemia[J]. Br J Ophthalmol, 1983, 67(2): 102-106. DOI: 10.1136/bjo.67.2.102.
20.	Blau-Most M, Gepstein R, Rubowitz A. Bilateral simultaneous central retinal vein occlusion in hyperviscosity retinopathy treated with systemic immunosuppressive therapy only[J]. Am J Ophthalmol Case Rep, 2018, 12: 49-51. DOI: 10.1016/j.ajoc.2018.08.006.
21.	Ratanam M, Ngim YS, Khalidin N, et al. Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia[J]. Br J Haematol, 2015, 170(3): 431-434. DOI: 10.1111/bjh.13307.
22.	Fenicia V, Balestrieri M, Perdicchi A, et al. Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's disease[J]. Case Rep Ophthalmol, 2013, 4(2): 64-69. DOI: 10.1159/000354066.

1. Gertz MA. Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2023, 98(2): 348-358. DOI: 10.1002/ajh.26796.
2. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994[J]. Cancer, 1998, 82(6): 1078-1081. DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3.
3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. DOI: 10.1182/blood-2016-01-643569.
4. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome[J]. Blood, 2012, 119(10): 2205-2208. DOI: 10.1182/blood-2011-04-347690.
5. Central Vein Occlusion Study Coordinating Center. Baseline and early natural history report. The Central Vein Occlusion Study[J]. Arch Ophthalmol, 1993, 111(8): 1087-1095. DOI: 10.1001/archopht.1993.01090080083022.
6. 中国抗癌协会血液肿瘤专业委员会中华医学会血液学分会中国华氏巨球蛋白血症工作组. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.Hematology Oncology Committee of China Anti- Cancer Association, Chinese Society of Hematology, Chinese Medical Association, Chinese Working Group of Walderström Macroglobulinemia. Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2022)[J]. Chin J Hematol, 2022, 43(8): 624-630. DOI: 10.3760/cma.j.issn.0253-2727.2022.08.002.
7. Pérez-Rueda A. Leukemic retinopathy secondary to hyperviscosity syndrome in acute lymphoblastic leukemia before and after treatment[J]. J Fr Ophtalmol, 2021, 44(3): 477-479. DOI: 10.1016/j.jfo.2020.04.039.
8. Shrestha S, Poddar E, Bashyal B, et al. Bilateral central retinal vein occlusion as an initial presentation of Waldenstrom macroglobulinemia: a case report[J]. J Med Case Rep, 2023, 17(1): 59. DOI: 10.1186/s13256-023-03778-4.
9. Hayreh SS, van Heuven WA, Hayreh MS. Experimental retinal vascular occlusion. I. pathogenesis of central retinal vein occlusion[J]. Arch Ophthalmol, 1978, 96(2): 311-323. DOI: 10.1001/archopht.1978.03910050179015.
10. Schatz MJ, Wilkins CS, Otero-Marquez O, et al. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis[J/OL]. Case Rep Ophthalmol Med, 2021, 2021: 6816195[2021-12-15]. https://pubmed.ncbi.nlm.nih.gov/34956683/. DOI: 10.1155/2021/6816195.
11. Baker PS, Garg SJ, Fineman MS, et al. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases[J]. Am J Ophthalmol, 2013, 155(3): 448-455. DOI: 10.1016/j.ajo.2012.09.018.
12. Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies[J]. J Clin Oncol, 2020, 38(11): 1198-1208. DOI: 10.1200/JCO.19.02314.
13. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenström macroglobulinemia[J]. J Clin Oncol, 2018, 36(27): 2755-2761. DOI: 10.1200/JCO.2018.78.6426.
14. Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase[J]. J Med Chem, 2019, 62(17): 7923-7940. DOI: 10.1021/acs.jmedchem.9b00687.
15. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study[J]. Blood, 2020, 136(18): 2038-2050. DOI: 10.1182/blood.2020006844.
16. Kumar SK, Callander NS, Adekola K, et al. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology[J/OL]. J Natl Compr Canc Netw, 2024, 22(1D): e240001[2024-01-01]. https://pubmed.ncbi.nlm.nih.gov/38244272/. DOI: 10.6004/jnccn.2024.0001.
17. Plante MM, Kimbrough EO, Agarwal AK, et al. Hyperviscosity syndrome induced bilateral visual and auditory impairment in therapy resistant Waldenström macroglobulinemia with MYD88 and CXCR4 mutations[J]. J Blood Med, 2023, 14: 639-648. DOI: 10.2147/JBM.S424072.
18. Chanana B, Gupta N, Azad RV. Case report: bilateral simultaneous central retinal vein occlusion in Waldenström's macroglobulinemia[J]. Optometry, 2009, 80(7): 350-353. DOI: 10.1016/j.optm.2008.12.007.
19. Thomas EL, Olk RJ, Markman M, et al. Irreversible visual loss in Waldenström's macroglobulinaemia[J]. Br J Ophthalmol, 1983, 67(2): 102-106. DOI: 10.1136/bjo.67.2.102.
20. Blau-Most M, Gepstein R, Rubowitz A. Bilateral simultaneous central retinal vein occlusion in hyperviscosity retinopathy treated with systemic immunosuppressive therapy only[J]. Am J Ophthalmol Case Rep, 2018, 12: 49-51. DOI: 10.1016/j.ajoc.2018.08.006.
21. Ratanam M, Ngim YS, Khalidin N, et al. Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia[J]. Br J Haematol, 2015, 170(3): 431-434. DOI: 10.1111/bjh.13307.
22. Fenicia V, Balestrieri M, Perdicchi A, et al. Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's disease[J]. Case Rep Ophthalmol, 2013, 4(2): 64-69. DOI: 10.1159/000354066.

Chinese Journal of Ocular Fundus Diseases

Latest Articles视网膜中央静脉阻塞的华氏巨球蛋白血症1例

Abstract Full text Figures/Tables Video References Cited by

Format

Content